Cigna complex lymphedema therapy Coverage Update

inv-01: Medically Necessary — Complex lymphedema therapy

Complex lymphedema therapy is considered medically necessary when ALL of the following are met:

Medically necessary criteria: Documented failure of a reasonable course of conservative medical management that includes home exercises, limb elevation, and compression garments.

Medically necessary criteria: The lymphedema is directly responsible for impaired functioning in the affected limb.

Medically necessary criteria: The complex lymphedema therapy is prescribed by or under the supervision of an appropriate healthcare provider.

inv-02: Duration and Frequency

Program frequency and limits

Duration/frequency: A program of complex lymphedema therapy provided 2-5 times per week for two weeks is generally considered medically necessary for the treatment of primary or secondary lymphedema in the absence of contraindications.2-5 sessions/week; typical 2-4 week program

Programs that go beyond a four-week period are generally considered not medically necessary.

inv-03: CDT (Phase I and II) — general coverage rationale

Covered when supported by clinical guidelines and evidence showing benefit

CDT as standard conservative treatment: Complete Decongestive Therapy (CDT) — comprising manual lymphatic drainage, multilayer compression bandaging/garments, exercise, skin care and education — is recognized as the main or 'gold standard' conservative treatment for lymphedema and is supported by international societies and guideline summaries.

Assessment of limb volume before, during and after treatment is recommended; evidence quality varies.

inv-04: IPC + bandages — alternative regimen

Alternative regimens shown non-inferior in trials

IPC plus bandages as alternative: Intermittent pneumatic compression (IPC) plus multilayer bandages demonstrated non-inferiority to traditional trimodal therapy (including MLD) in a randomized trial of stage II–III lymphedema (global mean PREV ≈ 63.9%) with similar adverse event profiles.

May inform coverage of IPC-based regimens when MLD is unavailable or contraindicated; 20-session regimens were studied.

inv-05: Adjunctive therapies: nighttime compression and MLD

Nighttime compression and MLD outcomes

Nighttime compression benefit: Addition of nighttime compression bandaging or a nighttime compression system garment to daytime compression produced statistically significant additional reduction in excess arm volume at 12 weeks compared with daytime garment alone.

High adherence reported in trial (≈95%).

MLD mixed evidence: Systematic reviews and meta-analyses report mixed results for MLD: some analyses show improvement in pain and incidence reduction, while volumetric benefits are inconsistent; volumetric reductions may be observed with prolonged treatment courses (e.g., ≥20 sessions or >2 weeks).≥20 sessions or >2 weeks

Evidence heterogeneous across studies and patient stages.

inv-06: Coverage stance for CDT and components

Covered when supported by clinical diagnosis and appropriate documentation

General coverage criteria for CDT: Coverage of CDT and its components is appropriate when there is a documented diagnosis of lymphedema supported by clinical assessment and measurable limb volume/circumference changes, and when CDT is provided by qualified clinicians.>10% limb volume difference cited in guideline summaries

Treatment outcomes should be reported in a standardized manner; evidence quality varies with larger benefits often seen in later-stage BCRL.

inv-07: Role of Manual Lymphatic Drainage (MLD)

MLD as a component of CDT — evidence summary

MLD outcomes: MLD demonstrates benefits for pain and may reduce incidence in some analyses, but evidence does not consistently show additional volumetric reduction when added to other CDT components except when treatment courses are prolonged (e.g., ≥20 sessions or >2 weeks).≥20 sessions associated with volume reduction

Some systematic reviews report limited added volume benefit of MLD within CDT; findings vary by stage and study quality.

inv-08: Adjunct therapies (LLLT, IPC, APCDs, Kinesio taping, Exercise)

Adjunct modalities have mixed-quality evidence; consider when CDT insufficient or as supplement

Low-Level Laser Therapy (LLLT): LLLT may provide short-term improvements in limb circumference/volume and pain versus sham or no treatment in some trials, but overall evidence quality is low to moderate and results are inconsistent; optimal dosing and long-term benefits remain uncertain.some trials used ~20 sessions

Further high-quality RCTs needed.

Intermittent pneumatic compression (IPC) and APCDs: IPC and advanced pneumatic compression devices (APCDs) show potential benefit for reduction and maintenance in some studies; evidence quality varies and larger multicenter trials are needed.maintenance-phase benefits suggested

May be considered as adjuncts to CDT depending on clinical context.

Kinesio taping (KT):

inv-09: Medically Necessary Services (when applicable policy criteria are met)

Considered medically necessary when criteria in the applicable policy statements listed above are met:

Medically necessary services: Manual therapy (CPT 97140) and complex lymphedema therapy (HCPCS S8950) are considered medically necessary when the applicable policy clinical criteria are met.

Provider must document that the patient meets the policy's clinical criteria, including diagnosis and prior conservative management.

Use of vasopneumatic (intermittent pneumatic) compression devices as part of complex lymphedema therapy (CLT/CDT) is considered not medically necessary. CPT code 97016 (application of vasopneumatic devices) is explicitly listed as not medically necessary for lymphedema treatment and may lead to claim denial when billed for this indication.

Evidence for Kinesio taping (KT) is limited and inconsistent. Systematic reviews and randomized trials report no clear volumetric advantage over standard compression bandaging or hosiery, and some analyses note increased skin complications; while some trials suggest benefits for function or comfort, overall evidence quality is low to moderate and does not support routine replacement of standard compression with KT.

The policy does not enumerate every excluded modality, but it notes that therapies lacking high-quality evidence or that have not shown improved outcomes compared with standard care may not be supported without documentation of medical necessity. Modalities judged experimental, investigational, or unproven in the cited literature (for example some LLLT findings and other adjuncts with low-quality data) require higher-quality evidence before routine coverage.

CPT code 97016 (Application of a modality; vasopneumatic devices) is specifically listed under the policy's Not Medically Necessary section and is not covered for the treatment of lymphedema.

Intensive CLT programs are expected to be time-limited. A program of complex lymphedema therapy provided 2–5 times per week for two weeks is generally considered medically necessary. Programs that extend beyond a four-week period are generally considered not medically necessary.

Several randomized trials and reviews failed to demonstrate a consistent additional volumetric benefit when intermittent pneumatic compression (IPC) or advanced/manual lymphatic drainage techniques were added to routine management. For example, pooled trials of IPC showed no consistent advantage over routine care, and some trials of enhanced MLD approaches found no clinically important additional benefit when added to other decongestive components.

Systematic reviews and meta-analyses show limitations in the evidence supporting routine use of manual lymphatic drainage (MLD) or exercise solely for volumetric reduction. While MLD may improve pain or incidence outcomes in some analyses, consistent volume reduction is generally observed only with prolonged or intensive treatment courses (e.g., analyses suggesting benefit with ≥20 sessions or >2 weeks), and overall findings are heterogeneous.

As noted elsewhere in the policy, CPT code 97016 (vasopneumatic devices) is explicitly listed as not medically necessary for lymphedema management and should not be billed as a covered CLT/CDT service.

Coding and Diagnostic Thresholds

Considered Medically Necessary when criteria are met - CPTCPTCovered

97140

Manual therapy techniques (eg, mobilization/manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes

Considered Medically Necessary when criteria are met - HCPCSHCPCSCovered

S8950

Complex lymphedema therapy, each 15 minutes

Considered Medically Necessary when criteria are met - CPTCPTCovered

97140

Manual therapy techniques (eg, mobilization/manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes

Considered Medically Necessary when criteria are met - HCPCSHCPCSCovered

S8950

Complex lymphedema therapy, each 15 minutes

Considered Not Medically NecessaryCPTNot Covered

97016

Application of a modality to 1 or more areas; vasopneumatic devices

inv-21: Limb volume diagnostic threshold — commonly >10% excess limb volume compared with contralateral limb.

Diagnostic threshold>10% excess limb volume compared with contralateral limb (commonly used in guideline summaries)

Supporting guideline findingMost guidelines recommend limb volume measurement with a >10% difference to confirm lymphedema diagnosis

Measurement recommendationAssess limb volume before, during, and after treatment to document diagnosis and response

inv-22: MLD treatment intensity threshold — ≥20 sessions or >2 weeks associated with benefit.

MLD intensity threshold≥20 sessions or treatment duration >2 weeks associated with statistically significant limb-volume reduction in some analyses

Evidence contextMeta-analyses and systematic reviews found volumetric benefit for MLD when treatment courses met or exceeded this intensity/duration

Clinical implicationProlonged/adequate course of MLD may be required to observe volumetric benefit; shorter courses often show mixed results

inv-23: Diagnostic limb volume threshold — >10% limb volume difference referenced in guidelines.

Diagnostic limb-volume cutoff>10% limb volume difference (commonly used in guidelines to confirm lymphedema)

Guideline supportSystematic guideline reviews reported most guidelines recommend a >10% limb-volume difference for diagnosis

Use in documentationDocument measured limb-volume difference to support diagnosis and eligibility for CDT

inv-24: Treatment session thresholds associated with benefit — ≥20 sessions or >15 sessions in some studies; >2 weeks duration also associated with benefit.

Primary treatment-session thresholds≥20 sessions associated with volumetric benefit; some studies report benefit with >15 sessions

Duration-based threshold>2 weeks total treatment duration also associated with significant volume reduction in analyses

Modality-specific noteLLLT studies reported improved outcomes with >15 sessions and specific dosing parameters in some analyses

Provider Requirements, Authorization, and Documentation

Prior Authorization

Prior Authorization for Intensive or Adjunct Interventions

Prior authorization may be required for intensive phases of complex decongestive therapy (CDT) and for adjunct or advanced devices/modalities. When CDT or adjunct interventions are prescribed, ensure any required prior authorization is obtained per payer rules before initiation of intensive reduction-phase programs or use of advanced pneumatic/compression devices or microsurgical procedures.

Prior authorization may apply to intensive reduction-phase CDT, adjunct devices (e.g., advanced pneumatic compression devices), or microsurgical interventions.
CDT must be prescribed by or under the supervision of an appropriate healthcare provider to be considered medical.

Prior Authorization

Authorization for CDT and Manual Therapy

When the policy criteria for CDT are met, CDT and manual therapy are considered medically necessary and should be authorized/documented accordingly. CPT 97140 (manual therapy/MLD) and HCPCS S8950 (complex lymphedema therapy, each 15 minutes) are listed as medically necessary when criteria are satisfied.

CPT 97140 — Manual therapy techniques (e.g., manual lymphatic drainage), 15 minutes.
HCPCS S8950 — Complex lymphedema therapy, each 15 minutes.

Denial Risk

Denial Risk / Not Medically Necessary Codes

No explicit denial triggers beyond codes and coverage rules are specified in this excerpt. Claims for services not accompanied by covered codes under this policy will be denied as not covered; separately, CPT 97016 (vasopneumatic devices) is listed as not medically necessary and may be denied if billed for lymphedema.

Claims submitted without covered diagnosis/procedure codes will be denied as not covered.
CPT 97016 — Application of a modality; vasopneumatic devices — listed as not medically necessary for lymphedema.

Documentation Required

Volume Assessment and Outcome Reporting

Assess and document limb volume before, during, and after treatment and report treatment outcomes in a standardized manner to evaluate effectiveness of therapy protocols.

Perform baseline limb volume or circumferential measurements prior to initiating CDT.
Document interval measurements during the intensive phase and at treatment completion to quantify response and guide care.
Report outcomes using standardized methods (e.g., percent reduction in excess volume).

Documentation Required

Clinical Measurement and Therapy Documentation

Support the diagnosis of lymphedema and medical necessity with clinical measurements and therapy documentation. Typical diagnostic criteria include comparison to the contralateral limb with >10% limb volume difference or other validated thresholds. Document prior conservative measures tried and changes in the patient's condition to justify skilled services.

Record limb volume or circumferential measurements (e.g., >10% excess volume compared to unaffected limb) and clinical findings supporting lymphedema versus other causes.
Document prior unsuccessful conservative management (elevation, bandaging, compression garments, exercises) and recent clinical changes.
Document that lymphedema is responsible for impaired limb function when claiming CDT as medically necessary.

Documentation Required

Measurement Instruments

Use validated measurement instruments with evidence of reliability/validity for lymphedema assessment. Preferred instruments include bioelectrical impedance spectroscopy (BIS), water volumetry, perometry, and tape measurement; BIS detects extracellular fluid changes in early (stage 1) lymphedema while volumetric methods detect changes from stage 2 onward.

Bioelectrical Impedance Spectroscopy (BIS) — sensitive for stage 1 extracellular fluid changes.
Water volumetry — research reference standard for upper-extremity volume measurement.
Perometry and standardized tape circumferential measurement — reliable for volume assessment in clinical practice.

Note

No Additional Documentation Requirements Specified in This Excerpt

No additional documentation requirements beyond those stated in this excerpt are specified here. Follow usual payer documentation expectations and any specific prior authorization instructions when present.

If additional documentation requirements are specified elsewhere in the full policy or in payer prior authorization instructions, comply with those requirements.
Maintain records of diagnoses, measurement data, prior conservative treatments, and treatment plans.

Note

Conservative Management Before Adjuncts

Conservative CDT components (skin care, compression bandaging/garments, exercise, self-MLD) should generally be used as first-line therapy. Adjuncts or intensive modalities are considered after an adequate trial of conservative management has failed.

Conservative management prerequisites include documented failure of a reasonable course of home exercises, limb elevation, and compression garments.
Phase I CDT (skin care, MLD, multilayer compression bandaging, ROM/exercise) followed by Phase II maintenance (skin care, compression garments, self-MLD, exercise) is the standard approach.

Note

Therapeutic Alternatives Evaluated

Therapeutic alternatives and comparative approaches have been evaluated in the literature. Some trials suggest intermittent pneumatic compression plus bandaging may be non-inferior to regimens including MLD for certain patients, and combinations of compression, exercise, and self-care are important components of management.

Intermittent pneumatic compression + multilayer bandage has been evaluated versus regimens including MLD; some studies found comparable reductions in excess volume.
Consider alternatives such as compression-only strategies, exercise, weight management, and self-management where clinically appropriate.

Definitions and Terminology

inv-46: Complex lymphedema therapy (CLT) / Complete decongestive therapy (CDT) — definition and component list.

DefinitionComplex lymphedema therapy (CLT)/Complete decongestive therapy (CDT) is a noninvasive, multi-component conservative treatment aiming to reduce and control limb swelling and restore function

Core componentsSkin and nail care; Manual Lymphatic Drainage (MLD); Multilayer compression bandaging/low-stretch compression garments; Therapeutic exercise; Patient education and self-management

Program structureTypically delivered in two phases: an intensive treatment (Phase I) followed by a maintenance/self-care phase (Phase II)

inv-47: Lymphedema staging — stages 0 through III and clinical notes.

Stage 0 (latent)Subclinical; impaired lymph circulation without evident swelling; evidence for CDT in Stage 0 is insufficient

Stage ISpontaneously reversible lymphedema with pitting edema and increased limb girth

Stage II and IIIStage II: spontaneously irreversible with tissue fibrosis and non-pitting edema; Stage III: lymphostatic elephantiasis with irreversible swelling and skin changes

inv-48: Phase I and Phase II CDT — description of phase I and II components.

Phase I (treatment)Characterized by skin and nail care, manual lymphatic drainage (MLD) with or without deeper techniques, multilayer compression bandaging, therapeutic exercise — typically intensive over 2–4 weeks

Phase II (maintenance)Characterized by skincare, use of low-stretch compression garments (stocking or sleeve), exercise, education and self-MLD to conserve results and avoid complications

Delivery notesPhase I aims at volume reduction; Phase II focuses on maintaining results via garments and self-management

inv-49: Complete Decongestive Therapy (CDT) — multimodal conservative treatment components summary.

Summary definitionComplete Decongestive Therapy (CDT) is a multimodal conservative treatment including MLD, low-stretch compression bandaging/garments, skin care, exercise, and education

ObjectiveReduce and control swelling in the affected limb and restore function; redirect and enhance lymph flow

Evidence noteCDT is recognized as the standard of care for lymphedema, though the contribution of individual components varies in evidence strength

inv-50: Manual Lymphatic Drainage (MLD) — definition and intended use.

DefinitionManual Lymphatic Drainage (MLD) is a light, massage-like technique performed for 30–60 minutes intended to stimulate residual lymphatic vessels and promote lymph flow as part of CDT

Intended useUsed during Phase I to assist volume reduction and as part of multimodal CDT; evidence for volumetric benefit is mixed and may depend on treatment intensity/duration

Evidence summarySystematic reviews show MLD improves pain and may reduce incidence in some settings; volumetric benefit often observed with ≥20 sessions or >2 weeks

inv-51: Bioelectrical Impedance Spectroscopy (BIS) — measurement instrument definition and use.

DefinitionBioelectrical Impedance Spectroscopy (BIS) is a measurement instrument that detects alterations in extracellular fluid and can identify stage 1 lymphedema

RoleUseful for early detection (stage 1) and monitoring changes in extracellular fluid as part of diagnostic and outcome assessment

Complementary useBIS complements volume-based measures which detect changes from stage 2 onward

inv-52: Water volumetry / perometry / tape measurement — measurement instruments and roles.

Water volumetryVolume displacement (water volumetry) is a reference test in research for upper-extremity lymphedema and detects volume changes starting from stage 2

PerometryPerometry provides validated limb-volume assessment suitable for detecting stage ≥2 changes

Tape (circumferential) measurementCircumferential tape measures are reliable and valid for limb-volume assessment and commonly used in clinical practice

inv-53: Complete decongestive therapy (CDT) — implied definition across literature citations (duplicate/confirmatory entry).

Implied multimodal definitionAcross the literature CDT is consistently described as a multimodal conservative treatment that may include MLD, compression bandaging/garments, exercise, skin care, and education

Consistency noteMultiple systematic reviews and clinical summaries reiterate CDT as the international standard despite heterogeneity in component-level evidence

Clinical practice implicationCDT delivery and component emphasis may vary by setting; documentation should specify components provided and patient response

inv-54: Guideline sources — National Cancer Institute, National Lymphedema Network, International Society of Lymphology, etc.

Included guideline sourcesNational Cancer Institute PDQ; National Lymphedema Network position statements; International Society of Lymphology guidance

Other evidence sourcesSystematic reviews, meta-analyses, randomized controlled trials and technology assessments cited across references

Use in policyThese guideline and consensus sources underpin the policy's recommendations for CDT as standard conservative care

OpenPayer

Therapy Services — Complex Lymphedema Therapy (Complete Decongestive Therapy)

Coverage Criteria — Complex Lymphedema Therapy

Coding and Diagnostic Thresholds

Provider Requirements, Authorization, and Documentation

Background and Epidemiology

Definitions and Terminology

Revision History